Nattokinase Reduces Clotting Risk by Lowering Blood Pressure

Nattokinase Reduces Risk of Blood Clots by Lowering Blood Pressure
High Blood Pressure is a Major Cause of Blood Clots
People with blood clots often suffer from high blood pressure also. This leads some people to believe that blood clots may also cause high blood pressure, but the reverse actually happens. High blood pressure causes blood clots.
When an individual suffers from high blood pressure, the blood travels throughout the body at a much higher speed putting too much force on the walls and lining of the arteries. The blood flowing at this higher speed and pressure can cause damage to arteries. The body often puts a layer of cholesterol to protect the lining from further damage.
Blood clots can develop in damaged arteries because now the lining isn’t smooth. When fats and cholesterol, which come from the foods you eat, enter your bloodstream they can catch on the unsmooth surface and accumulate which narrows the arteries and weakens arterial walls. Over time, the narrow arteries prevent or limit blood flow throughout the body. Limiting or preventing the blood from flowing freely throughout the body speeds up atherosclerosis, a condition that makes your arteries get harder, narrower, and clogged with fatty plaque eventually leading to blood clots. Hypertension also makes you more likely to have atrial fibrillation. It causes blood to collect in the heart, where a clot can form.
Research Shows that Nattokinase Can Reduce Blood Pressure
Below is a summary of two human research studies confirming beneficial impact of nattokinase on high blood pressure. This in turn reduces the risk of blood clots.
Nattokinase Reduces Both Systolic And Diastolic Blood Pressure
Executive Summary
In this randomized double-blind clinical study, 74 subjects with high blood pressure were divided in two groups- treatment and control. Treatment group took 100 mg of nattokinase daily for 8 weeks while the control group took a placebo. While both systolic and diastolic blood pressure declined in the treatment group, the decline in the diastolic blood pressure (from 86mmHg to 81mmHg) was statistically significant and even more so among males consuming nattokinase.
Ashvin Health’s Bloodflow Formula contains 100 mg of nattokinase per serving.
Title
Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial.
Source
Integr Blood Press Control. 2016 ;9:95-104. Epub 2016 Oct 13. PMID: 27785095
Author(s)
Gitte S Jensen, Miki Lenninger, Michael P Ero, Kathleen F Benson
Article Affiliation
Gitte S Jensen
Abstract
OBJECTIVE: The objective of this study is to evaluate the effects of consumption of nattokinase on hypertension in a North American hypertensive population with associated genetic, dietary, and lifestyle factors. This is in extension of, and contrast to, previous studies on Asian populations.
MATERIALS AND METHODS: A randomized, double-blind, placebo-controlled, parallel-arm clinical study was performed to evaluate nattokinase. Based on the results from previous studies on Asian populations, 79 subjects were enrolled upon screening for elevated blood pressure (BP; systolic BP ≥130 or diastolic BP ≥90 mmHg) who consumed placebo or 100 mg nattokinase/d for the 8-week study duration. Blood collections were performed at baseline and 8 weeks for testing plasma renin activity, von Willebrand factor (vWF), and platelet factor-4. Seventy-four people completed the study with good compliance.
RESULTS: Consumption of nattokinase was associated with a reduction in both systolic and diastolic BP. The reduction in systolic BP was seen for both sexes but was more robust in males consuming nattokinase. The average reduction in diastolic BP in the nattokinase group from 87 mmHg to 84 mmHg was statistically significant when compared to that in the group consuming placebo, where the average diastolic BP remained constant at 87 mmHg (P<0.05), and reached a high level of significance for males consuming nattokinase, where the average diastolic BP dropped from 86 mmHg to 81 mmHg (P<0.006). A decrease in vWF was seen in the female population consuming nattokinase (P<0.1). In the subpopulation with low plasma renin activity levels at baseline (<0.29 ng/mL/h), an increase was seen for 66% of the people after 8-week consumption of nattokinase (P<0.1), in contrast to only 8% in the placebo group.
CONCLUSION: The data suggest that nattokinase consumption in a North American population is associated with beneficial changes to BP in a hypertensive population, indicating sex-specific mechanisms of action of nattokinase’s effect on vWF and hypertension.
Nattokinase lowers systolic and diastolic blood pressure in human subjects
Executive Summary
In this randomized clinical study, 86 subjects with high blood pressure were divided in two groups- treatment and control. Treatment group took 100 mg of nattokinase daily while the control group took a placebo. At the end of 8 weeks, the systolic blood pressure declined by 5.55mmHg and diastolic blood pressure declined by 2.84 in the treatment group.
Ashvin Health’s Bloodflow Formula contains 100 mg of nattokinase per serving.
Title
Effects of nattokinase on blood pressure: a randomized, controlled trial.
Source
J Cell Physiol. 2010 Jun;223(3):771-8. PMID: 18971533
Author(s)
Ji Young Kim, Si Nae Gum, Jean Kyung Paik, Hyo Hee Lim, Kyong-Chol Kim, Kazuya Ogasawara, Kenichi Inoue, Sungha Park, Yangsoo Jang, Jong Ho Lee
Abstract
The objective of this study was to examine the effects of nattokinase supplementation on blood pressure in subjects with pre-hypertension or stage 1 hypertension. In a randomized, double-blind, placebo-controlled trial, 86 participants ranging from 20 to 80 years of age with an initial untreated systolic blood pressure (SBP) of 130 to 159 mmHg received nattokinase (2,000 FU/capsule) or a placebo capsule for 8 weeks. Seventy-three subjects completed the protocol. Compared with the control group, the net changes in SBP and diastolic blood pressure (DBP) were -5.55 mmHg (95% confidence interval [CI], -10.5 to -0.57 mmHg; p<0.05) and -2.84 mmHg (CI, -5.33 to -0.33 mmHg; p<0.05), respectively, after the 8-week intervention. The corresponding net change in renin activity was -1.17 ng/mL/h for the nattokinase group compared with the control group (p<0.05). In conclusion, nattokinase supplementation resulted in a reduction in SBP and DBP. These findings suggest that increased intake of nattokinase may play an important role in preventing and treating hypertension.